
Opinion|Videos|March 4, 2024
SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer
Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5











